Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment-Reference-Cited by-同舟云学术

Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment

Published:2017-03 Issue:2 Volume:6 Page:206-212
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Talal Andrew H.¹,Venuto Charles S.²³,Younis Islam⁴

Affiliation:

1. Division of Gastroenterology, Hepatology, and Nutrition; Department of Medicine; University at Buffalo; Buffalo NY USA

2. Center for Human Experimental Therapeutics; University of Rochester; Rochester NY USA

3. AIDS Clinical Trials Group Pharmacology Specialty Laboratory; New York State Center of Excellence in Bioinformatics and Life Sciences; School of Pharmacy and Pharmaceutical Sciences; University at Buffalo; Buffalo NY USA

4. Office of Clinical Pharmacology; Office of Translational Sciences; Center for Drug Evaluation and Research; US Food and Drug Administration; Silver Spring MD USA

Funder

Troup Fund of the Kaleida Health Foundation

National Institutes of Health

National Institute of Allergy and Infectious Diseases

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.336/fullpdf

Reference45 articles.

1. US FDA Center for Drug Evaluation and Research Guidance for industry: Pharmacokinetics in patients with impaired hepatic function. Study design, data analysis, and impact on dosing and labeling http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm

2. Transection of the oesophagus for bleeding oesophageal varices;Pugh;Br J Surg,1973

3. Liver fibrosis and repair: immune regulation of wound healing in a solid organ;Pellicoro;Nat Rev Immunol,2014

4. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement;Albillos;Hepatology,2003

5. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis;Mookerjee;Gut,2003

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec;Clinical Pharmacokinetics;2024-05-09

2. Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults;Clinical Pharmacology in Drug Development;2024-01-23

3. Safe Prescribing in Patients with Kidney and Hepatic Diseases;Principles and Practice of Pharmacovigilance and Drug Safety;2024

4. The influence of comorbid disease on premature death due to natural and unnatural causes in persons with schizophrenia;Schizophrenia Research;2023-07

5. Impact of Organ Impairment on the Pharmacokinetics of Therapeutic Peptides and Proteins;The AAPS Journal;2023-05-26